Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Six years after establishing its India office, Geneva-based Drugs for Neglected Diseases Initiative (DNDi) is planning to expand its presence to cater to the drug development needs of the Indian population as well as neighboring countries like Bangladesh and Sri Lanka

You may also be interested in...



Indian Lobby Groups Laud Global Efforts To Eliminate NTDs But Call For Stronger Grassroots Delivery Mechanism

India lobby groups question whether global efforts to eliminate neglected tropical diseases will provide concrete local solutions, noting that drugs are just a part of the problem.

Pharma Joins Forces With WHO, Global Governments In Unprecedented Effort To Control Neglected Tropical Diseases

Big Pharma join hands with WHO, global governments and foundations in unprecedented effort to wipe out neglected tropical diseases.

Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel